Title:
抗腫瘍性複素環イミダゾール系化合物の医薬塩
Document Type and Number:
Japanese Patent JP6740471
Kind Code:
B2
Abstract:
The present invention relates to the field of pharmaceutical synthesis, and in particular to an antitumor heterocyclic imidazole compound (I), namely: a pharmaceutical salt of 4-(3-(4-(1H-imidazo[4,5-b]pyridine-5-yl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin e-1(dihydro)-ketone, a preparation method therefore, a pharmaceutical composition thereof and a use thereof in the preparation of antitumor drugs. The pharmaceutical salt of the compound (I) in the present invention may be used in the preparation of a medicament for the treatment or prevention of conditions which can be improved by inhibiting PARP activity.
Inventors:
Sakaki Entertainment
Lee Wen
Qin
Lee Wen
Qin
Application Number:
JP2019520395A
Publication Date:
August 12, 2020
Filing Date:
October 11, 2017
Export Citation:
Assignee:
Shanghai Hui Lun Life Technology Co., Ltd.
International Classes:
C07D471/04; A61K31/502; A61P35/00; A61P35/02; A61P43/00
Domestic Patent References:
| JP6610975B2 | ||||
| JP2006519827A |
Foreign References:
| CN104003940A |
Other References:
J. Med. Chem.,2008年,51,6581-6591
Attorney, Agent or Firm:
Patent Business Corporation Tani/Abe Patent Office